Thomas Jaki

Thomas Jaki

University of Cambridge

H-index: 43

Europe-United Kingdom

About Thomas Jaki

Thomas Jaki, With an exceptional h-index of 43 and a recent h-index of 38 (since 2020), a distinguished researcher at University of Cambridge, specializes in the field of Pre-clinical Statistics, Early Phase Clinical Trials, Adaptive Designs.

His recent articles reflect a diverse array of research interests and contributions to the field:

Bayesian Model Averaging for Partial Ordering Continual Reassessment Methods

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised …

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Predicting individual responses to treatment for alcohol use disorder: Project MATCH

Predicting Individual Treatment Effects: Challenges and Opportunities for Machine Learning and Artificial Intelligence

Joint TITE-CRM: A Design for Dose Finding Studies for Therapies with Late-Onset Safety and Activity Outcomes

Early phase clinical trials in oncology: Realising the potential of seamless designs

A Bayesian multi‐arm multi‐stage clinical trial design incorporating information about treatment ordering

Thomas Jaki Information

University

Position

Programme Leader at MRC Biostatistics Unit and Professor of Statistics at Lancaster University

Citations(all)

29233

Citations(since 2020)

27941

Cited By

11289

hIndex(all)

43

hIndex(since 2020)

38

i10Index(all)

116

i10Index(since 2020)

94

Email

University Profile Page

Google Scholar

Thomas Jaki Skills & Research Interests

Pre-clinical Statistics

Early Phase Clinical Trials

Adaptive Designs

Top articles of Thomas Jaki

Bayesian Model Averaging for Partial Ordering Continual Reassessment Methods

arXiv preprint arXiv:2403.00701

2024/3/1

Thomas Jaki
Thomas Jaki

H-Index: 25

Pavel Mozgunov
Pavel Mozgunov

H-Index: 6

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Nature Communications

2024/1/31

Predicting individual responses to treatment for alcohol use disorder: Project MATCH

2024/1/23

Predicting Individual Treatment Effects: Challenges and Opportunities for Machine Learning and Artificial Intelligence

2024/1/22

Joint TITE-CRM: A Design for Dose Finding Studies for Therapies with Late-Onset Safety and Activity Outcomes

Statistics in Biopharmaceutical Research

2024/3/20

Thomas Jaki
Thomas Jaki

H-Index: 25

Early phase clinical trials in oncology: Realising the potential of seamless designs

European Journal of Cancer

2023/8/1

A Bayesian multi‐arm multi‐stage clinical trial design incorporating information about treatment ordering

Statistics in Medicine

2023/7/20

Pavel Mozgunov
Pavel Mozgunov

H-Index: 6

Thomas Jaki
Thomas Jaki

H-Index: 25

Exploring the issues that influence how people with rare neurological conditions engage in physical activity

Disability and Rehabilitation

2023/7/3

An Alternative to Traditional Sample Size Determination for Small Patient Populations

Statistics in Biopharmaceutical Research

2023/7/3

Holly Jackson
Holly Jackson

H-Index: 1

Thomas Jaki
Thomas Jaki

H-Index: 25

Treating intrusive memories after trauma in healthcare workers: a Bayesian adaptive randomised trial developing an imagery-competing task intervention

Molecular Psychiatry

2023/7

Online error rate control for platform trials

Statistics in medicine

2023/6/30

Point estimation for adaptive trial designs II: practical considerations and guidance

2023/6/30

Backfilling cohorts in phase I dose-escalation studies

Clinical Trials

2023/6

Thomas Jaki
Thomas Jaki

H-Index: 25

Bayesian sample size determination using commensurate priors to leverage preexperimental data

Biometrics

2023/6

Haiyan Zheng
Haiyan Zheng

H-Index: 4

Thomas Jaki
Thomas Jaki

H-Index: 25

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (preprint)

The Lancet Diabetes & Endocrinology

2023/12/1

Development process of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE (DosE FIndiNg Extensions) study

2023/4

Updating the probability of study success for combination therapies using related combination study data

Statistical Methods in Medical Research

2023/4

Thomas Jaki
Thomas Jaki

H-Index: 25

SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol

BMJ open

2023/3/1

See List of Professors in Thomas Jaki University(University of Cambridge)

Co-Authors

academic-engine